Alcohol consumption and related disorders in Iran: Results from the National Surveillance of Non-Communicable Diseases' Survey (STEPs) 2016.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
07
2021
accepted:
28
06
2022
entrez:
24
3
2023
pubmed:
25
3
2023
medline:
25
3
2023
Statut:
epublish
Résumé
Alcohol consumption is a public health concern which is illegal in Iran. Moreover, due to cultural and religious beliefs, the available population-based research findings on alcohol consumption are inadequate. We aimed to provide an estimate on alcohol consumption using a large-scale population-based survey in Iran. The National Surveillance of Non-Communicable Risk Factors in Iran was a population-based survey conducted in 2016. The epidemiologic distribution of alcohol consumption and its related disorders were assessed using weighted survey methods and multiple logistic regression models. Age standardized rates were calculated using Iran's national population census in 2016. At the national level, the prevalence rates of lifetime and current alcohol consumption were 8.00% (95% CI: 7.67-8.32) and 4.04% (95% CI: 3.81-4.27), respectively. The highest prevalence was reported among 25 to 34 year-olds. Individuals of higher socioeconomic status consumed significantly greater levels of alcohol. At provincial level, the highest and lowest percentages of the current alcohol drinking rates in Iran's provinces were, 23.92% (95% CI: 17.56-30.28) and 0.4% (95% CI: 0-1.18) in males, 1.58% (95% CI: 0.22-2.94) and 0% in females, respectively. In urban regions, the highest alcohol consumption rate was more than 22 times greater than the lowest alcohol consumption rate. Current alcohol drinkers were 2 times more prone to injury as compared to nondrinkers (ORadj: 2.0, 95%CI: 1.7, 2.3). In Iran, the prevalence of alcohol consumption is low, although there is a considerable variation of alcohol consumption at provincial level as well as in different gender groups. Therefore, preventive WHO-recommended measures should be adopted more seriously by vulnerable groups.
Sections du résumé
BACKGROUND
BACKGROUND
Alcohol consumption is a public health concern which is illegal in Iran. Moreover, due to cultural and religious beliefs, the available population-based research findings on alcohol consumption are inadequate. We aimed to provide an estimate on alcohol consumption using a large-scale population-based survey in Iran.
MATERIALS AND METHODS
METHODS
The National Surveillance of Non-Communicable Risk Factors in Iran was a population-based survey conducted in 2016. The epidemiologic distribution of alcohol consumption and its related disorders were assessed using weighted survey methods and multiple logistic regression models. Age standardized rates were calculated using Iran's national population census in 2016.
RESULTS
RESULTS
At the national level, the prevalence rates of lifetime and current alcohol consumption were 8.00% (95% CI: 7.67-8.32) and 4.04% (95% CI: 3.81-4.27), respectively. The highest prevalence was reported among 25 to 34 year-olds. Individuals of higher socioeconomic status consumed significantly greater levels of alcohol. At provincial level, the highest and lowest percentages of the current alcohol drinking rates in Iran's provinces were, 23.92% (95% CI: 17.56-30.28) and 0.4% (95% CI: 0-1.18) in males, 1.58% (95% CI: 0.22-2.94) and 0% in females, respectively. In urban regions, the highest alcohol consumption rate was more than 22 times greater than the lowest alcohol consumption rate. Current alcohol drinkers were 2 times more prone to injury as compared to nondrinkers (ORadj: 2.0, 95%CI: 1.7, 2.3).
CONCLUSION
CONCLUSIONS
In Iran, the prevalence of alcohol consumption is low, although there is a considerable variation of alcohol consumption at provincial level as well as in different gender groups. Therefore, preventive WHO-recommended measures should be adopted more seriously by vulnerable groups.
Identifiants
pubmed: 36962484
doi: 10.1371/journal.pgph.0000107
pii: PGPH-D-21-00427
pmc: PMC10021244
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0000107Informations de copyright
Copyright: © 2022 Rezaei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declared no conflict of interest.
Références
Drug Alcohol Rev. 2018 Nov;37(7):874-878
pubmed: 30027547
BMC Med. 2016 Nov 24;14(1):193
pubmed: 27881133
BMC Public Health. 2006 May 03;6:118
pubmed: 16670030
Clin Toxicol (Phila). 2012 Nov;50(9):823-31
pubmed: 22992104
BMC Public Health. 2013 Oct 10;13:950
pubmed: 24112134
Iran J Public Health. 2014 May;43(5):579-89
pubmed: 26060759
Medicina (B Aires). 2014;74(4):287-92
pubmed: 25188654
Addiction. 2016 Oct;111(10):1715-6
pubmed: 26948525
Asian Pac J Cancer Prev. ;18(7):1913-1917
pubmed: 28749620
PLoS One. 2017 Jan 31;12(1):e0170892
pubmed: 28141834
J Stud Alcohol Drugs. 2017 May;78(3):387-388
pubmed: 28499103
Int J Health Policy Manag. 2016 Aug 17;6(2):97-102
pubmed: 28812784
Lancet Public Health. 2019 Apr;4(4):e175-e176
pubmed: 30954139
Arch Iran Med. 2017 Sep;20(9):608-616
pubmed: 29048923
Alcohol Res. 2013;35(2):155-73
pubmed: 24881324
Am J Public Health. 2013 Feb;103(2):206-14
pubmed: 23237151
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):597-601
pubmed: 26425466
Alcohol Alcohol. 2020 Jun 25;55(4):347-348
pubmed: 32400874
Addiction. 2017 Feb;112(2):222-228
pubmed: 27442501
Drug Alcohol Depend. 2017 Jul 1;176:48-54
pubmed: 28514696
Addiction. 2014 Feb;109(2):206-15
pubmed: 23941363
J Am Coll Cardiol. 2017 Aug 22;70(8):913-922
pubmed: 28818200
World Health Organ Tech Rep Ser. 2007;(944):1-53, 55-7, back cover
pubmed: 17970166
Subst Abuse Treat Prev Policy. 2019 Dec 16;14(1):56
pubmed: 31842979
Lancet. 2014 Nov 29;384(9958):1927-8
pubmed: 25435451
Clin Psychol Rev. 2004 Dec;24(8):981-1010
pubmed: 15533281
J Psychoactive Drugs. 2019 Jul-Aug;51(3):290-297
pubmed: 30798779
Lancet. 2017 Dec 16;390(10113):2643-2654
pubmed: 28943267
Int J Cancer. 2006 Aug 15;119(4):884-7
pubmed: 16557583
Addiction. 2015 Feb;110(2):279-88
pubmed: 25355374
Curr Atheroscler Rep. 2017 Mar;19(3):13
pubmed: 28210975
Alcohol Alcohol Suppl. 2006 Oct-Nov;41(1):i47-55
pubmed: 17030503
J Drug Educ. 2020 Mar-Jun;49(1-2):30-42
pubmed: 32779985
J Stud Alcohol Drugs. 2016 Mar;77(2):185-98
pubmed: 26997174
J Epidemiol Community Health. 2017 Aug;71(8):729-735
pubmed: 28679541